Pharmacology of cabozantinib

A tétel rövid nézete
dc.contributor.advisorMegyeri, Attila
dc.contributor.advisordeptDebreceni Egyetem::Általános Orvostudományi Kar::Farmakológiai és Farmakoterápiai Intézet
dc.contributor.authorNouzari, Mohammad
dc.contributor.departmentDE--Általános Orvostudományi Kar
dc.contributor.opponentSzentmiklósi, József András
dc.contributor.opponentHalasi, Barbara Dóra
dc.contributor.opponentdeptDebreceni Egyetem::Általános Orvostudományi Kar::Farmakológiai és Farmakoterápiai Intézet
dc.contributor.opponentdeptDebreceni Egyetem::Általános Orvostudományi Kar::Igazságügyi Orvostani Intézet
dc.date.accessioned2023-05-09T12:00:18Z
dc.date.available2023-05-09T12:00:18Z
dc.date.created2023-03-03
dc.description.abstractCabozantinib is an antineoplastic drug discovered and developed by Exelixis. It comes in two formulations Cometriq® (capsules) and Cabometyx® (tablets) which are not bioequivalent hence not interchangeable. They both contain cabozantinib as their active ingredient, but each contain different subcomponents causing a change in the pharmacokinetics and pharmacodynamics. Cometriq® was approved in 2012 and Cabometyx® in 2017 by the FDA. Some tumors are produced due to the overactivity of receptor and intracellular tyrosine kinases. Cabozantinib is part of the multikinase inhibitor group of drugs which could be better than the use of single kinase inhibitor depending on several factors in certain situations. Multiple clinical studies performed proved the effectivity of cabozantinib compared to placebo or other multikinase inhibitor to be presenting better outcomes in several tumors. Tumors primarily targeted are renal cell carcinoma, hepatocellular carcinoma, and differentiated thyroid carcinoma by Cabometyx® and medullary thyroid carcinoma by Cometriq®.
dc.description.correctorLB
dc.description.courseáltalános orvos
dc.description.courselangangol
dc.description.degreeegységes, osztatlan
dc.format.extent45
dc.identifier.urihttps://hdl.handle.net/2437/352429
dc.language.isoen
dc.rights.accessHozzáférhető a 2022 decemberi felsőoktatási törvénymódosítás értelmében.
dc.subjectmultikinase
dc.subjectantineoplastic
dc.subjectcabozantinib
dc.subject.dspaceDEENK Témalista::Orvostudomány::Farmakológia
dc.titlePharmacology of cabozantinib
Fájlok
Gyűjtemények
Theses (Faculty of Medicine)